Emergent BioSolutions Inc. is one of four companies collaborating to provide hyperimmune globulin products for a new federal clinical trial that will test the safety, tolerability and efficacy of a combination treatment regimen for COVID-19. The regimen consists of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, according to the National Institute of Allergy and Infectious Diseases (NIAID), the division of the National Institutes of Health (NIH) that is sponsoring and funding the Phase 3 trial known as Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC. Remdesivir is currently recommended by NIAID for treating certain hospitalized patients with COVID-19.

 

 

Bill Oxford/iStock

Read more…